Comments
The Centre has granted import duty exemption on Remdesivir API, Injections and specific inputs used in the manufacture of this anti-viral drug, which finds use in COVID19 treatment.
Remdesivir, which is not a life saving drug, is an experimental investigational drug granted emergency use authorisation for use in COVID19 treatment. It is recommended to be used only in hospital setting and advised for patients who are moderately sick and receiving oxygen.
This import duty exemption will be available till October 31, the Finance Ministry has said in a notification issued on Tuesday.
The latest import duty waiver move comes on the back of Centre’s recent intervention to make Remdesivir injectable more affordable for patients during the current second wave of COVID19. In the wake of reports of shortages and black marketing of this anti-viral drug, the government had few days back nudged the seven domestic manufacturers of Remdesivir to voluntarily slash the MRP by 25-70 per cent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.